San Diego-based Viking Therapeutics marked alone as a serious competitor inside the weight loss drug marketplace in February following revealing promising details from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered as being a weekly injection and in March the compa